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A B S T R A C T
Only in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As
options regarding treatments are increasing so are the challenges in selecting the right treatment option for each patient and not the least, understanding the optimal
time-point and sequence of applying available treatments. Critically, without reliable methods that enable sequential monitoring of evolving genotypes in individual
patients, we will never reach effective personalised driven treatment approaches. This review focuses on the clinical implications of prostate cancer genomics and the
potential of cfDNA in facilitating treatment management.
1. Prostate cancer
Prostate cancer (PC) is the most commonly diagnosed cancer and
the second leading cause of cancer related death in men. Prostate
specific antigen (PSA) is detected in the blood from men and levels are
increased both in benign prostatic hyperplasia (BPH) and due to tumour
development in the prostate. Increased PSA levels are thus followed up
by further examinations and pathological evaluation of tissue biopsies
from the prostate to confirm presence of cancer lesions. As many men
today test their PSA, a vast majority of men are diagnosed with loca-
lized and less advanced, often indolent, tumours (Moore et al., 2009).
Early PC detection is the best chance of cure, and elevated PSA le-
vels in the blood may indicate presence of PC prior to any symptoms.
PSA screening is therefore an attractive strategy in preventing mortality
but a large proportion of men that are diagnosed with PC will never
develop from an indolent to a lethal disease within their lifetime
(Schröder et al., 2014). The test thus leads to vast overtreatment of
men, and still men with aggressive PC are missed. Having surgical or
radiological treatment of the prostate is frequently followed by poorer
quality of life and many men unnecessarily suffer these consequences
due to overdiagnoses (Loeb et al., 2014). There is thus a need of stra-
tegies to further stratify patients at risk and spare those with indolent
tumours from unnecessary biopsies and radical treatments. Although
there is an increasing number of available commercial diagnostic tests
based on molecular markers, their benefit on survival and cost-effec-
tiveness are yet not properly evaluated in head-to-head comparisons
(Carlsson and Roobol, 2017; Cucchiara et al., 2018).
In men who are diagnosed with metastatic disease or who progress
after their initial treatment there is still no cure. Androgen deprivation
treatment (ADT) is a potent treatment for metastatic PC (mPC) and has
until 2004 been the only life-prolonging systemic treatment for mPC
(Nuhn et al., 2019). Although most tumours respond to ADT, and in
some men the response lasts for several years, some men have primary
resistance to treatment and invariably all men develop secondary re-
sistance and progress to castration-resistant prostate cancer (CRPC).
In recent years approved treatment options prolonging survival for
men with mCRPC have significantly increased, mainly with taxane
chemotherapy (Johann Sebastian De Bono et al., 2010; de Leeuw et al.,
2015; Petrylak et al., 2004) and second-generation androgen inhibiting
agents abiraterone and enzalutamide (Johann S. De Bono et al., 2011;
Scher et al., 2012). Furthermore, novel treatment options are being
investigated with additional androgen targeting, and strategies to in-
hibit other pathways as mono- or combinational therapies.
PSA is used as a marker of disease recurrence and subsequently
informs on treatment-response in patients. Neuroendocrine tumours are
an aggressive subset of PC that do not secrete PSA (J. M. Mosquera
et al., 2013). Critically, PSA has limitations as a biomarker in this set-
ting, and can furthermore not guide on treatment selection.
Conclusively, there is an unmet need for biomarkers in early disease
for better stratifying patients with aggressive tumours from those not in
need of further intervention.
In advanced stages biomarkers are needed for early detection of
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recurrence, treatment selection, tracking treatment response/early de-
tection of treatment resistance.
Real-time monitoring could enable fast adaptation of treatment
strategies in order to cumulatively prolong survival and quality of life in
patients with PC.
2. Molecular characterization of prostate cancer
2.1. Primary prostate cancer
PC is a multifocal, molecularly heterogeneous disease (Abeshouse
et al., 2015; Baca et al., 2013; Cooper et al., 2015; Lindberg et al., 2013)
so that each tumour can be composed of many different tumours, all
with individually different potential to grow and progress. Extensive
integrative molecular characterization of PC has been made possible by
the technical developments in next-generation sequencing (NGS) which
has substantially increased our understanding of PC biology.
In primary PC ETS transcription factor fusions and rearrangements
are the most frequently occurring aberrations, with fusion between the
promotor of gene TMPRSS2 and ERG being detected in approximately
50% of patients (Gasi et al., 2011; Hermans et al., 2009; Tomlins et al.,
2005). TMPRSS2 is a prostate specific and androgen regulated gene and
located 3 Mbp from ERG and the fusion leads to overexpression of a
truncated ERG protein. It is thought to be one of the earliest molecular
alterations, detected already in prostate intraepithelial neoplasia (PIN),
the precursor stage of PC (Cerveira et al., 2006; DeMarzo et al., 2003;
J.-M. Mosquera et al., 2008). Copy number variations (CNVs) with
chromosome 8p24 gain (including MYC) and 8q21 losses (including
NKX3-1) are other frequently occurring aberrations in primary tumours
as well as focal CNVs like PTEN, TP53 and RB1 loss. The mutation rate
in primary prostate is relatively low compared to other tumour types
with SPOP mutations being the most frequent; occurring in 6–15% of
tumours (Barbieri et al., 2012; Taylor et al., 2010). Molecular char-
acterization of primary PC by The Cancer Genome Atlas Research
Network (TCGA) could categorize 74% of primary cancers studied into
seven distinct subtypes (n = 333) with SPOP mutations detected ex-
clusively in ETS-fusion negative samples. Possible clinically actionable
aberrations in AR, DNA-repair, PIK3 and MAPK signalling pathways
were variably affected across all defined subtypes although SPOP and
FOXA1 mutated patients where associated with the highest AR tran-
scriptional activity (Abeshouse et al., 2015) in this cohort.
The clinical relevance of the different subtypes in primary PC is
complex and still subject for investigation. Additional aberrations to
TMPRSS2-ERG fusion seem necessary for cancer onset and data on the
predictive value of the fusion are conflicting (Gasi Tandefelt et al.,
2014). Some events like 3p13 loss (including genes FOXP1, RYBP,
SHQ1) is associated with ERG + subset and tumours harbouring both
aberrations manifest a more aggressive molecular subtype (Krohn et al.,
2013). Furthermore, prognostic gene expression signatures are identi-
fied within ERG + subtype (Gasi Tandefelt et al., 2013; Kamoun et al.,
2018) across several independent cohorts.
Copy number burden has also been shown to better predict poorer
progression (Hieronymus et al., 2014) than PSA or Gleason grade and a
recent study found that whole chromosome-arm aneuploidy in primary
tumours could identify patients that where 5-fold more likely to pro-
gress to lethal disease (Stopsack et al., 2019). Prospective data and
comparison between novel tests are necessary to evaluate their benefit.
In order to acquire relevant data, these tests need to be cost-efficient
and easy to use in the clinical setting.
2.2. Tumour evolution and metastatic prostate cancer
Tumours progression can be described as a trajectory following
Darwinian evolution (Greaves and Maley, 2012) where cancer cell-
clones adapt to selective pressures that are applied through changed
metabolic rate, new environment, treatments etc. Tumours genomic
composition is thus changed over time and may require a different
treatment strategy from the one initially selected.
Although primary tumours are multifocal and heterogeneous, Liu
et al. showed by characterizing copy number patterns from multiple
metastasis in each individual that metastasis are of monoclonal origin
(Liu et al., 2009) and acquire sub-clonal events throughout progression.
More recent data supports these findings and additionally shows that
convergent evolution occurs under selective pressure of ADT where
several metastases develop androgen-receptor (AR) aberrations in-
dependently (Bova et al., 2016; Grasso et al., 2012; Gundem et al.,
2015; Kumar et al., 2016) over time.
In a study by Haffner et al., identified the focus responsible for the
lethal metastatic spread in one patient and demonstrated that the origin
was not the high-grade bulk tumour but a small, lower grade focus in
the prostate, strengthening the relevance of investigating the molecular
background of tumour tissue in addition to pathological evaluation
(Haffner et al., 2013).
After the initial metastatic lesion, the metastatic spread likely fol-
lows seed-to-soil with more molecular similarities between metastasis
that are in close proximity than to the primary tumour they originated
from (Gundem et al., 2015).
Comprehensive molecular characterization of PC metastasis shows
many similarities to primary disease, regarding pathways that are af-
fected, but also some important differences. One difference seen is an
increased mutation rate from approximately 1 mutation/Mb
(Abeshouse et al., 2015) to 4.4 mutations/Mb (D. Robinson et al.,
2015).
Most striking difference is the emergence of AR CN gains and mu-
tations in over 60% of patients which are absent in primary tumours.
Enrichment of aberrations in TP53, PTEN, and PI3K/AKT pathway is
observed as well as increased numbers of low-frequent (occurring in
less that 3%) recurrent mutations (Armenia et al., 2018).
An interesting finding was that also the germline samples that
where sequenced from PC patients had an enrichment of mutations in
the DNA-repair pathway (Pritchard et al., 2016).
Across all exome sequencing reports, overlapping data is emerging
of recurrent events driving PC, as well as a combination of less frequent
drivers unique to each individual that require large datasets to detect.
Merging previously published data with novel whole-genome sequences
(WGS, n = 930) revealed 22 novel aberrations as well as non-coding
mutations in FOXA1 and NEAT1 acting as drivers in PC (Wedge et al.,
2018). Recently an amplification was identified by WGS in an enhancer
620 kB upstream of AR resulting in AR transcriptional activation in
81% of mCRPC tumours. This finding suggests that up to 85% of
mCRPC have de-regulated AR-pathway by duplications or mutations
(D. A. Quigley et al., 2018), a finding supported by recent data (De
Laere et al., 2019).
Neuroendocrine PC is a subset of tumours that do not express AR or
PSA, lead to visceral metastasis, and associate with particularly poor
clinical outcome. Adenocarcinomas can, as a mechanism of treatment
resistance to androgen deprivation and AR targeting treatments, ac-
quire neuroendocrine features. The genetic characteristics of this ag-
gressive subset of tumours are amplification of MYCN and losses of RB1
and TP53 function (Beltran et al., 2011; Ku et al., 2017; Puca et al.,
2019).
3. Cell-free DNA and clinical implications of PC genomics
3.1. Cell-free DNA in prostate cancer
Low pass whole-genome and targeted deep sequencing can detect
circulating tumour DNA (ctDNA) in men with metastatic PC (mPC) but
not in localized disease (Hennigan et al., 2019) thus the utility of cfDNA
in early prostate cancer is currently limited. Recent cfDNA studies show
differences in nucleosome footprints (Snyder et al., 2016; Ulz et al.,
2019) between healthy and tumour cells which may expand the use of
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cfDNA to early detection.
In metastatic PC up to 90% of metastasis are spread to the bone
making tissue sampling difficult and, in many cases, not possible. DNA
sequencing studies with contemporarily collected biopsies from me-
tastasis and plasma have high overlap between detected aberrations in
circulating cell-free (cfDNA) and tissue (Frenel et al., 2015; Wyatt et al.,
2017), demonstrating that cfDNA is a surrogate source of tumour ma-
terial. Aberrations can be missed in cfDNA due to low levels of tumour
DNA fraction in some samples, but can also provide additional in-
formation that is missed in tissue due to under-sampling
(Vandekerkhove et al., 2019).
Different tumour clones that are present in one patient are re-
presented in the circulation and can be tracked over time (Carreira
et al., 2014; Frenel et al., 2015). Serial collection of cfDNA can there-
fore be used as a tool to study the biology behind cancer progression
and emerging treatment resistance mechanisms. Another potential of
ctDNA is to facilitate the translation of prostate cancer genomics into
clinically practical multi-purpose biomarkers.
3.2. Clinical implications of cancer genomics
3.2.1. AR-pathway
In addition to ADT that is initially effective in most men, several
studies have now shown that the more effective androgen targeting
treatments like abiraterone and enzalutamide, and systemic treatments
like docetaxel significantly prolong symptom-free disease and overall
survival when applied in combination with ADT in men with hormone-
sensitive metastatic disease (Fizazi et al., 2019; N. D. James et al., 2017;
Nicholas D. James et al., 2016; van Soest and de Wit, 2015).
AR aberrations are not detected in primary tumours or hormone-
naïve metastasis but appear in tumours after ADT with AR CN gain in
30% (Visakorpi et al., 1995) and point mutations in approximately 20%
(D. Robinson et al., 2015; Taplin et al., 1999) of cases. The most
common mutations are T878A and H875Y but the ligand-binding do-
main (LDB) of AR is a hot-spot for additional mutations. Progesterone
and cortisol stimulated L702H (Van De Wijngaart et al., 2010) have
particularly high activation by cortisol as double mutant with T878A
(Matias et al., 2002), two mutations often co-occurring at progression to
abiraterone in cfDNA studies (Carreira et al., 2014; Romanel et al.,
2015; Wyatt et al., 2016). In patients who become resistant to abir-
aterone a “steroid switch” to the glucocorticoid dexamethasone from
prednisolone leads to continued response (Lorente et al., 2014) in 40%
of cases. The mechanism behind this is not known but one possibility
could be that particular point mutations (or combination thereof) could
inform on those men who might benefit from a “steroid switch” (Zhao
et al., 2000).
Additional recurrent AR mutations are the bicalutamide-induced
W742 C/L (Carreira et al., 2014), F877L that is associated with en-
zalutamide treated patients (Wyatt et al., 2016) and the less char-
acterized V716M (Culig et al., 1993), among others (Shi et al., 2002).
W742C/L, H875Y, F877L and T878A act as agonists instead of an-
tagonists to androgen deprivation treatments but the mutations in
L702H, V716M, H875Y and T878A also result in promiscuous receptors
that can be activated by other ligands like oestradiol, progesterone or
hydrocortisone (Shi et al., 2002). Functional studies of AR mutant
clones that emerge at resistance to novel antiandrogens such as F877L
and double mutant F877L/T878A demonstrate that these clones are
sensitive to previously used antiandrogen bicalutamide highlighting
possibilities to prolong successful anti-androgen treatment for sub-
groups of patients (Lallous et al., 2016).
The androgen receptor expresses several splice variants (AR-Vs)
both in normal prostate and in cancer tissue (Watson et al., 2015). AR-
V7, a constitutively active splice variant, has been correlated with
primary resistance to abiraterone and enzalutamide treatment when
detected in circulating tumour cells (CTC's) (Antonarakis et al., 2014).
Numbers of CTC's as well as levels of cfDNA in the circulation (as
marker of tumour burden) have been shown to predict response to
treatments (Johann S. De Bono et al., 2008; De Laere, Oeyen, et al.,
2019; Mehra et al., 2018; Torquato et al., 2019) and several studies
show that AR aberrations associate with treatment resistance to abir-
aterone and enzalutamide (Conteduca et al., 2017; Romanel et al.,
2015; Wyatt et al., 2016).
The largest sequencing effort of mCRPC tumour tissue to date
(n = 444) investigated the clinical outcome of several common genetic
aberrations in abiraterone and enzalutamide treated patients (Abida
et al., 2019). AR point mutations and CN gain associated to treatment
resistance in concordance to previous reports, but did not associate with
overall survival. Although the expression of AR-V7 and other splice
variants increased with treatment to both taxanes and androgen tar-
geting drugs, the expression did not associate with treatment resistance
or overall survival in this cohort.
3.2.2. DNA damage repair genes
DNA damage repair (DDR) aberrations occur in 10–19% (Abeshouse
et al., 2015; Armenia et al., 2018) of primary cancers and in up to 25%
of castration-resistant PC (CRPC) (Armenia et al., 2018; D. Robinson
et al., 2015). In recent studies that by whole-exome sequencing, char-
acterized germline samples collected from men with metastatic PC the
frequency of DDR mutations was increased from that in general popu-
lation (3%), to ~8–12% (Pritchard et al., 2016). The increase in pre-
valence suggests that carriers might be at higher risk to develop me-
tastatic disease and, if so, DDR gene sequencing could in the future
select patients for a more aggressive treatment regime early.
Poly (ADP-ribose) polymerase (PARP) inhibitors hinder the release
of DNA repair protein PARP1. In combination with DDR impaired tu-
mour cells this inhibition induces programmed cell death (Hopkins
et al., 2015). In a phase II study (TOPARP), the PARP inhibitor olaparib
was evaluated for responses in a cohort of fifty patients that had pre-
viously received taxane treatment and 98% had also received en-
zalutamide or abiraterone prior to enrolment. In patients that har-
boured defects in BRCA2/1, ATM, PALB2 and other DDR genes
(n = 16) response to treatment was reached in 88% of cases (Mateo
et al., 2015). During this trial sequential plasma was collected and the
follow-up study elegantly demonstrates the potential of cfDNA as a
multi-purpose biomarker (Goodall et al., 2017). It demonstrates con-
cordance between detected aberrations in circulation and simulta-
neously collected tissue, strengthening the value of screening cfDNA in
order to identify patients with DDR germline and somatic aberrations.
Subclones with genomic changes that restored DDR function emerged
at progression in cfDNA samples identifying mechanisms of resistance
that were not detected in tissue (Goodall et al., 2017; D. Quigley et al.,
2017).
Platinum-based chemotherapy cross-links DNA, stalling the re-
plication fork (Lord and Ashworth, 2016) and is an effective treatment
in DDR defected ovarian and breast cancers. Individual cases have been
reported with remarkable responses to cis-platin (Beltran et al., 2015)
and carboplatin in prostate cancer patients, all harbouring different
DNA-repair deficiencies (Zafeiriou et al., 2019).
Approximately 2–5% of mCRPC patients have mismatch repair
(MMR) or micro-satellite instability (MSI) with mutations in MSH2 and
MSH6 (Pritchard et al., 2014; D. Robinson et al., 2015). Although small
percentage of patients, this could be an opportunity for many in-
dividuals to gain a treatment option with Pembrolizumab, a PD-1 in-
hibitor that is approved for use in any tumour type with MMR defects
(Le et al., 2017).
CDK12 mutated tumours are present in 3–7% of mCRPC (D. R.
Robinson et al., 2017; Wu et al., 2018) and have a distinct im-
munophenotype making them another promising candidate for im-
munotherapy. Clinical implications of CDK12 were investigated in a
cohort that combined tissue and cfDNA sequencing data from three
different centres (Melissa A. Reimers et al., 2019). CDK12 aberrated
patients had shorter time to metastasis and CRPC suggestive of a more
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aggressive subtype but did not reach significance as an independent
variable in multivariable analysis. mCRPC patients stratified by biallelic
loss of CDK12 will be enrolled in the IMPACT trial, NCT03570619
(Melissa Andrea Reimers et al., 2019), to assess the response rate to the
combination of immunotherapies nivolumab (anti-PD-1) and ipili-
mumab (anti-CTLA-4).
3.2.3. PI3K pathway
PTEN loss and deregulation of other PI3K pathway genes (PIK3CA/
B, AKT, PIK3RI) are significantly higher in mCRPC (~49%) than pri-
mary tumours (below 20%) pointing toward activation of PI3K pathway
having an important role in tumour progression (Abeshouse et al.,
2015; Abida et al., 2019; D. Robinson et al., 2015). PTEN loss are the
most common aberration and is essential for tumour development in
ETS positive tumours in in vivo studies and in aggressive subtypes of PCs
(Ahearn et al., 2016; Ku et al., 2017; Zong et al., 2009; Zou et al., 2017).
A strategy in combating PI3K driven neoplasm is inhibiting AKT, the
junction of PI3K signalling pathway. Recent understanding of the
crosstalk between PI3K inhibition and AR signalling suggests that a
combination of androgen and AKT inhibitors could be a successful
strategy for a subset of patients (Carver et al., 2011; Schwartz et al.,
2015). Trials investigating the combination for mCRPC are undergoing
and will determine possible association with PTEN loss and effect of
treatment (NCT02525068), and the benefit of AKT inhibition in a priori
selected patients with AKT mutations (NCT03310541).
4. Discussion and future perspectives
In recent years there has been a tremendous increase of data on PC
genetics. There is a high level of consistency in the reports on recur-
rently found aberrations in PC (Abida et al., 2019; Armenia et al., 2018;
Chen et al., 2019; D. R. Robinson et al., 2017) but yet novel discoveries
are made through integrative efforts that are combining several in-
dependent cohorts in order to increase study power (Wedge et al.,
2018). The increased understanding of PC biology and evolution of the
disease have consequently led to opportunities to develop new treat-
ments against novel promising targets, of re-purposing already existing
treatments and of gaining survival benefit by administrating treatments
earlier in the disease pathway.
While exploratory research is adding to our understanding and in-
creasing treatment targets and treatment options (Adams et al., 2019),
feasible and fast means of mapping the background of each patient to
enable the correct treatment strategy at the right time are necessary.
Novel technical developments have enabled detection of tumour DNA
in plasma cfDNA and provide a powerful tool in tracking changes over
time. Importantly, clinical relevance of the underlying genetics needs to
be elucidated as outcomes for patients with mCRPC are still dismal and
novel treatment strategies urgently needed.
Circulating cell-free DNA and other liquid biopsies have enabled
tracking of different emerging genetic aberrations present in the tumour
in “real-time”. Despite that cfDNA only provides complementary in-
formation to tissue and other liquid biopsies (reviewed in (Heitzer
et al., 2017)) there is growing evidence for the biomarker utility of this
minimally invasive source of tumour material.
Mechanisms of resistance have been tracked and better understood
due to the possibility of cfDNA sequential tumour sampling (Annala
et al., 2017; Carreira et al., 2014; De Laere et al., 2019; Frenel et al.,
2015; Lallous et al., 2016; Mayrhofer et al., 2018; Romanel et al., 2015)
and several described studies have leveraged cfDNA to identify poten-
tially clinically valuable biomarkers (Table 1). The results of these
biomarker studies are inconsistent and there is yet not a single study
that prospectively validates identified markers. Possible explanations to
this inconsistency are; the use of different sequencing platforms and
assays, applying different thresholds for calling variants and missing
important co-occurring events due to use of relatively small targeted
panels in most studies. Ta
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Methodological advances in DNA sequencing (Filges et al., 2019;
Mansukhani et al., 2018) and finding better ways of identifying the
tumour fraction in cfDNA samples (Annala et al., 2018) can further
improve the sensitivity to detect timely changes in the future.
In breast cancer tracking individual mutations could predict recur-
rence after curative treatment as early as 8 months prior to clinical
recurrence. This prediction was superior when tracking events identi-
fied in sequential cfDNA samples over those aberrations identified in
primary tumour tissue (Garcia-Murillas et al., 2015). Recently, the same
group showed the utility of ctDNA tracking to predict relapse in early
breast cancer (Garcia-Murillas et al., 2019) on average 10.7 months
prior to clinical criteria. An initial WGS and whole-exome sequencing
(WES) study on cfDNA in early prostate cancer failed to detect ctDNA in
early PC (Hennigan et al., 2019) but other targeted approaches that
enable higher sequencing depth might be better suitable for this pur-
pose. More data is needed to investigate the potential of relapse de-
tection with ctDNA in prostate cancer.
Combination of drugs based on individual genome data and com-
putational predictive models is an approach to successfully keep
treatment resistance at bay in HIV (Bock and Lengauer, 2012). This
strategy could be explored for managing treatment resistance in cancer.
Computational models that predict mechanisms of resistance in
cancer, identify that ten resistant subclones are present in any radi-
ologically detectable lesion (Bozic and Nowak, 2014) confirming the
difficulty of single targeting treatment strategies. Tracking emerging
subclones in sequentially collected cfDNA confirmed these findings
(Bozic et al., 2016) and point toward the need of expanding treatment
choices and investigating tolerable treatment combinations. Treatment
strategies that take advantage of PC evolution trajectories could better
keep tumour growth at bay with decreased treatment doses (Enriquez-
Navas et al., 2016; Gatenby et al., 2019) in order to enable treatment
combinations.
Furthermore, computational models implementing PC genomics
data is accelerating drug discovery for PC by predicting potentially
successful re-purposing of already approved drugs and identifying
promising novel drug targets (Wedge et al., 2018; Workman et al.,
2019), steadily increasing treatment options.
Even though the data on genetic characterization and its clinical
relevance is encouraging, none of the genetic markers are yet pro-
spectively validated and consistency in the definition of clinically re-
levant genetic markers are lacking.
In summary, the ability to track genomic changes over time by
cfDNA opens tremendous opportunities in learning about PC vulner-
abilities that could be exploited for patient benefit but analytical
standardization and prospective clinical trials are urgently warranted.
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